hotspot -WSS

hotspot

author：leisure time 2025-10-06 19:04:55 - browse：5

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Cloning humans is technically possible. It's curious no one has tried

knowledge

WSS

The strategy behind pharma's lawsuits over drug pricing reform

Colonoscopy at 40? Study finds a possible benefit

Weight bias in eating disorder treatment complicated by new weight loss drugs

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

A fraught question for the kids of Alzheimer’s: Is it coming for us?

There’s no way to know how good AI health technologies are

Wikipedia

hotspot

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Akero's treatment for NASH falls short in cirrhosis study

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Akero's treatment for NASH falls short in cirrhosis study

The high cost of giving birth even with insurance

Why drug prescriptions should include diagnoses

Duchenne breakthrough therapy leaves behind pioneering families

European regulators recommend Amylyx's ALS drug be rejected

After affirmative action ruling, medical educators look to 'holistic review'

What would happen to your eyes if you looked at the solar eclipse?

explore

European regulators consider appeal over Amylyx ALS drug

Weight bias in eating disorder treatment complicated by new weight loss drugs

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

What's changing in Medicare's open enrollment this year?

Cloning humans is technically possible. It's curious no one has tried

What would happen to your eyes if you looked at the solar eclipse?

focus

Wikipedia

knowledge

explore